Clinical Report: FDA Permits New Sunscreen Ingredient After 20 Years
Overview
The FDA has added bemotrizinol to the OTC sunscreen monograph, marking the first new active ingredient since the late 1990s. Bemotrizinol offers protection against UVA and UVB radiation and is recognized as safe and effective for adults and children aged 6 months and older.
Background
The addition of bemotrizinol is significant as skin cancer rates continue to rise. The FDA's action reflects ongoing efforts to enhance consumer safety and efficacy in sunscreen formulations.
Data Highlights
No numerical data provided in the source material.
Key Findings
- Bemotrizinol is the first new sunscreen active ingredient added to the OTC monograph since the late 1990s.
- It provides protection against both UVA and UVB radiation.
- The ingredient has low systemic absorption following topical use.
- Bemotrizinol is recognized as generally safe and effective for use in sunscreen products for adults and children aged 6 months and older.
- The FDA's approval process for bemotrizinol was expedited under the Coronavirus Aid, Relief, and Economic Security Act.
Clinical Implications
Healthcare professionals should be aware of the new sunscreen options available, including those containing bemotrizinol.
Conclusion
The FDA's addition of bemotrizinol to the OTC sunscreen monograph represents a significant advancement.
Related Resources & Content
- FDA, FDA, 2026 -- FDA Expands Sunscreen Options for the First Time in 20 Years
- American Academy of Dermatology, AAD, 2026 -- American Academy of Dermatology Statement on the Importance of Sun Protection
- Journal of Clinical Oncology, 2010 -- Reduced Melanoma After Regular Sunscreen Use: Randomized Trial Follow-Up
- The ASCO Post — FDA Commissioner Margaret A. Hamburg’s Statement on the Surgeon General’s Call to Action to Prevent Skin Cancer
- The ASCO Post — Capitalizing on Increased Interest in Skin Cancer During Summer to Reeducate People About Sunscreens and ‘Smart Sun Strategies’
- Contact Lens Spectrum — FDA Accepts NDA for Tenpoint's Brimochol PF
- Optometric Management — Practice Pulse: Tips, Trends & New You Can Use
- FDA Commissioner Margaret A. Hamburg’s Statement on the Surgeon General’s Call to Action to Prevent Skin Cancer
- Capitalizing on Increased Interest in Skin Cancer During Summer to Reeducate People About Sunscreens and ‘Smart Sun Strategies’
- FDA Accepts NDA for Tenpoint's Brimochol PF
- FDA Expands Sunscreen Options for the First Time in 20 Years | FDA
- American Academy of Dermatology Statement on the Importance of Sun Protection
- Reduced Melanoma After Regular Sunscreen Use: Randomized Trial Follow-Up | Journal of Clinical Oncology
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
